Who is sponsoring NCT01631227?

NCT01631227 is sponsored by Abbott.

What condition does NCT01631227 study?

NCT01631227 studies Essential Hypertension.

What drugs are being tested in NCT01631227?

Interventions: Eprosartan, Eprosartan Mesylate, Placebo Eprosartan mesylate, Placebo Eprosartan.

What is the status of NCT01631227?

NCT01631227 is currently COMPLETED.

Last reviewed 2014-07-18 · How we verify

A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension

NCT01631227 Phase 3 COMPLETED Results posted

Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Details

Lead sponsor	Abbott
Phase	Phase 3
Status	COMPLETED
Enrolment	665
Start date	2012-06
Completion	2013-04

Conditions

Essential Hypertension

Interventions

Eprosartan
Eprosartan Mesylate
Placebo Eprosartan mesylate
Placebo Eprosartan

Primary outcomes

Assess the Therapeutic Equivalence of Eprosartan (a New Formulation Containing Only the Active Moiety Eprosartan) With Eprosartan Mesylate (Currently Marketed Formulation) on Change of Sitting Diastolic Blood Pressure (DBP) From Baseline — 8 weeks
Change from baseline of diastolic blood pressure (DBP), sitting

Countries

Germany, Russia, United Kingdom